OUR SCIENCE

Hillstream Oncology

Next Generation of Targeted Cancer Therapies

HS1940: Revolutionizing Anti-PD-1 Therapy with Undruggable Epitopes

Unlocking undruggable epitopes presents a formidable challenge in the realm of immunotherapy. Inspired by nature’s ingenuity, HS1940, is a potentially groundbreaking knob domain platform.

Traditional antibodies often struggle to access challenging epitopes effectively. However, HS1940 leverages ultralong complementary determining region (CDR) H3 sequences, enabling precise targeting of novel epitopes. Drawing inspiration from the unique antigen recognition mechanisms of cows, our approach overcomes the limitations of traditional antibody therapy.

With knob domains, we’re shrinking the size of antibody fragments but also expanding the scope of therapeutics. Through this groundbreaking research we’re reshaping the future of anti-PD1 therapy and paving the way for novel, cutting-edge cancer treatments.

advanced cancers respond to anti-PD-1 therapies

20 %

PD-1 inhibitors ORR range from 10% to 40% in different tumor types.

10 %

The incidence of AEs can affect up to 70% receiving PD-1 inhibitors

0 %

40%

advanced cancers respond to anti-PD-1 therapies

40%

PD-1 inhibitors ORR range from 10% to 40% in different tumor types.

70%

The incidence of AEs can affect up to 70% receiving PD-1 inhibitors

HS3215: Next-Generation Anti-HER2/ HER3 Bispecific Antibody

The ErbB family of cell surface proteins, notably HER2 (human epidermal growth factor receptor) and HER3, stands as one of the most significant targets in oncology. Over the years, the development of antibodies against HER2 has marked a pivotal milestone in cancer therapy, starting with the groundbreaking approval of HERCEPTIN® (trastuzumab) in 1998. Today, with innovative additions like PERJETA®, KADCYLA®, and PHESGO®, this family of therapeutics has grown into a multibillion dollar market.

However, traditional approaches to targeting HER2 and HER3 often encounter limitations due to shared epitopes with trastuzumab. HS3215, an anti-HER2/HER3 bispecific antibody represents a paradigm shift which targets different functional epitopes of HER2 and HER3, than trastuzumab offering a novel approach to cancer therapy.

of all breast cancers are HER2 positive

15 %

recurrence within 10 years of initial diagnosis

20 %

bsAb products approved by the FDA

20%